Scholarlink

Purpose <p>Sinonasal neuroendocrine carcinomas (SNECs) are rare and aggressive malignancies with heterogeneous histopathology and limited evidence guiding optimal treatment. This study aims to characterize clinicopathological features, treatment patterns, and prognostic factors using a large population-based database.</p> Methods <p>We queried the SEER database (2000–2022) for histologically confirmed SNECs. Kaplan-Meier analysis was used to estimate overall survival (OS) and disease-specific survival (DSS). Univariate and multivariate Cox models were employed to identify independent prognostic factors.</p> Results <p>A total of 389 cases were identified, mostly male (58.4%) with a median age of 60 years and nasal cavity as primary site (48.1%). Neuroendocrine carcinoma not otherwise specified (50.1%) was the most frequent, followed by small cell (35.0%) and large cell carcinoma (10.5%). Nearly 38% of patients presented with metastatic disease. Surgery, radiotherapy, and chemotherapy were administered in 54.1%, 66.9%, and 69.9% of cases, respectively. Kaplan-Meier analysis showed improved OS and DSS in patients with localized/locally advanced stage, lower tumor grade, nasal cavity primary site, and those treated with surgery, radiotherapy (particularly adjuvant), or chemotherapy (all <i>p</i> &lt; 0.05). In multivariate models, primary sites outside the nasal cavity were independently associated with worse OS and DSS, while surgery and radiotherapy remained the only treatment modality significantly associated with improved outcomes.</p> Conclusion <p>In this large population-based study, SNECs were characterized by advanced-stage presentation and use of multimodal therapy. Radiotherapy was independently associated with improved OS/DSS in multivariable models, supporting aggressive local treatment in SNECs and underscoring the need for therapeutic strategies tailored to disease stage and tumor location.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic factors and survival outcomes of multimodal treatment in sinonasal neuroendocrine tumors in a population based SEER analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月22日

查看全文
  • Francesca Carosi,
  • Laura Fabbri,
  • Giuseppe Lamberti,
  • Elisa Andrini,
  • Elisabetta Nobili,
  • Daria Maria Filippini,
  • Davide Campana

摘要

Purpose

Sinonasal neuroendocrine carcinomas (SNECs) are rare and aggressive malignancies with heterogeneous histopathology and limited evidence guiding optimal treatment. This study aims to characterize clinicopathological features, treatment patterns, and prognostic factors using a large population-based database.

Methods

We queried the SEER database (2000–2022) for histologically confirmed SNECs. Kaplan-Meier analysis was used to estimate overall survival (OS) and disease-specific survival (DSS). Univariate and multivariate Cox models were employed to identify independent prognostic factors.

Results

A total of 389 cases were identified, mostly male (58.4%) with a median age of 60 years and nasal cavity as primary site (48.1%). Neuroendocrine carcinoma not otherwise specified (50.1%) was the most frequent, followed by small cell (35.0%) and large cell carcinoma (10.5%). Nearly 38% of patients presented with metastatic disease. Surgery, radiotherapy, and chemotherapy were administered in 54.1%, 66.9%, and 69.9% of cases, respectively. Kaplan-Meier analysis showed improved OS and DSS in patients with localized/locally advanced stage, lower tumor grade, nasal cavity primary site, and those treated with surgery, radiotherapy (particularly adjuvant), or chemotherapy (all p < 0.05). In multivariate models, primary sites outside the nasal cavity were independently associated with worse OS and DSS, while surgery and radiotherapy remained the only treatment modality significantly associated with improved outcomes.

Conclusion

In this large population-based study, SNECs were characterized by advanced-stage presentation and use of multimodal therapy. Radiotherapy was independently associated with improved OS/DSS in multivariable models, supporting aggressive local treatment in SNECs and underscoring the need for therapeutic strategies tailored to disease stage and tumor location.